NATiAS establishes original mass production technology for oligonucleotide APIs.
NATiAS (Chuo-ku, Kobe), a CDMO (Contract Development and Manufacturing Organization) of oligonucleotide APIs, has nealy established its own technology for liquid-phase synthesis suitable for mass production. It can shorten the synthesis process and increase productivity and purity compared to conventional solid-phase synthesis. The company will complete the automated equipment within a few years and build a mass production plant in Japan. The company plans to start manufacturing oligonucleotide APIs as well as CpG ODN (vaccine adjuvant). Although solid-phase synthesis is the mainstream method in the oligonucleotide industry, NATiAS will leverage its own liquid-phase synthesis method, which is superior for mass production, to capture the growing market demands of oligonucleotide therapeutics.